Anticancer Therapies – Products

ERS Genomics Limited is pleased to announce a new license agreement with Lepton Pharmaceuticals LTD.

A screening tool developed in research led at the University of Strathclyde, UK could increase the number of tests on a solid tumor sample by up to 50 times.

Vaccizone has selected Exothera S.A. to fast-track process development of its SARS-CoV-2 vaccine for European clinical trials.

Sino Biological has developed an array of high-quality Proteins, Antibodies, Genes, Lysate, and qPCR Primer Pairs to support the study of IFN-Is.

Avacta Group plc announces that the first-in-human Phase I trial of AVA6000 Pro-doxorubicin will advance to the third dose cohort following a positive review of the safety data from the dosing of the second cohort.

Expansion of Specific Lymphocyte Populations With 4Cell® Nutri-T Xeno-Free, Serum-Free Medium

The success of CAR T-cell therapy requires efficient expansion of specific subpopulations of patient-derived immune cells.

Cancer immunotherapy, especially the use of immune checkpoint inhibitors, has been successful in improving the treatment landscape of malignancies.

SomaLogic has announced it has signed a licensing agreement with OncoHost.

Natural killer (NK) cells are immune cells capable of killing target cells and can be genetically modified to express chimeric antigen receptors (CARs). CAR NK-cell therapy is an innovative type of cancer immunotherapy for solid tumors and hematological malignancies.

Discovery of novel immunotherapies that specifically target and enhance the T cell response against cancer is a rapidly expanding research area. Robust and relevant in vitro models for evaluation of these immunotherapies is essential throughout their development.